Skip to content

Effect Of Virtual Reality Distraction on Symptom Control and Anxiety in Children With Leukemia

Effect Of Virtual Reality Distraction on Symptom Control and Anxiety in Children With Leukemia: A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05818748
Acronym
VR-Ege
Enrollment
40
Registered
2023-04-19
Start date
2023-03-30
Completion date
2024-03-30
Last updated
2023-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Symptom Cluster

Brief summary

This study aim to evaluate the effect of virtual reality distraction on symptom management and anxiety in children aged 7-18 years with leukemia.

Detailed description

While the virtual reality initiative was applied to the children in the study group, no harm was given to the children in the control group. The virtual reality distraction method will not be applied to the control group. After the child and his family are informed about the study, their written informed consent will be obtained. When the patients were admitted to the clinic the day before chemotherapy treatment was started, the symptom screening scale and anxiety scale will be applied. Control Group: The researcher stated that no additional procedure will be applied to the children in the control group and that the symptom screening scale and anxiety measurement will be obtained by explaining that he/she should evaluate the scale every day for 3 days. VR group; A distraction intervention will be applied for 10-15 minutes once a day with VR glasses. The symptom screening scale and anxiety measurement will be obtained by explaining that he/she should evaluate the scale every day for 3 days.

Interventions

DEVICEvirtual reality

virtual reality distraction

Sponsors

Ege University
CollaboratorOTHER
Dokuz Eylul University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Randomised

Eligibility

Sex/Gender
ALL
Age
7 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Pediatric patients aged 7-18 years receiving leukemia treatment in the Pediatric Hematology Service * 4 weeks after diagnosis (not in the induction phase) * No need for blood product transfusion (less than 8 mg/dl for hematological malignancies, less than 7 mg/dl for oncological malignancies) * Consent to voluntarily participate in the study and written consent from the child and parent

Exclusion criteria

* The child has a physical and psychological deficit that will prevent him from wearing glasses to watch virtual reality * Having a symptom of nausea and vomiting * Being in a terminal period * Undergoing a surgical operation * Unwillingness to participate in the study * Having a history of vertigo (having a history of train, motion sickness) * The child and family do not know Turkish

Design outcomes

Primary

MeasureTime frameDescription
Change in symptom clusterduring the 1st, 2nd and 3rd days of chemotherapy treatmentSymptom by Symptom Screening Tool(8-18) in SSPedi-Pediatric Patients with Cancer
Change in anxiety(during the 1st, 2nd and 3rd days of chemotherapy treatment)anxiety by State-Trait Anxiety Inventory for Children

Countries

Turkey (Türkiye)

Contacts

Primary ContactGülçin Özalp Gerçeker, pHD
gulcinozalp@gmail.com905306411368
Backup ContactGülçin Özalp Gerçeker, pHD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026